与此同时，该公司正在寻求收购以扩充其产品线。2024年，该公司以32亿美元收购了Morphic Therapeutics，获得了一种用于治疗炎症性肠病的实验性药物。此外，该公司还斥资24亿美元收购了 Dice Therapeutics，后者是一家开发口服银屑病疗法的公司。 礼来公司表示，免疫学是其关键增长领域，该公司希望在糖尿病和肥胖症治疗领域取得巨大成功的基础 上，进一步拓展业务。这些成功吸引了投资者和患者的关注。该公司目前已销售多种治疗关节炎和银屑 病等炎症性疾病的药物，包括Taltz，但Taltz的关键专利保护将在未来几年内到期。 据报道，礼来(LLY.US)正就以超过10亿美元的价格收购Ventyx Biosciences(VTYX.US)进行深入谈判，以 拓展其在免疫学领域的业务。截至发稿，Ventyx股价在美股夜盘交易中上涨62.59%，至16.34美元。这 家总部位于圣地亚哥的生物技术公司专注于研发治疗克罗恩病和类风湿性关节炎等炎症性疾病的药物， 按此价格计算，其市值将增加4.339亿美元。Ventyx收购案的报道正值制药行业准备参加在旧金山举行 的摩根大通医疗保健大会之际，该大会历来是并购交易 ...

Market Overview - U.S. stocks had a positive trading session, with the Dow Jones Industrial Average increasing by 480 points, or 0.99%, to 49,462.08. The NASDAQ rose by 0.65% to 23,547.17, and the S&P 500 increased by 0.62% to 6,944.82 [1] SanDisk Corporation - SanDisk shares surged by 27.56%, closing at $349.63, with an intraday high of $352 and a low of $288.50. In after-hours trading, the stock rose an additional 2.3% to $357.75. The stock's performance was bolstered by comments from Nvidia's CEO regarding the demand for memory and storage [2] - Recent options market activity showed significant bullish sentiment, with 40% of 110 trades opened with bullish expectations. Analysts have mixed views, with price targets ranging from $235 to $300 following SanDisk's 2025 spin-off from Western Digital [3] Alumis - Alumis shares skyrocketed by 95.31%, closing at $16.23, with an intraday high of $22.30 and a low of $15.27. In after-hours trading, the stock gained nearly 2.6% to $16.65. The increase followed positive topline results from Phase 3 trials of envudeucitinib for moderate-to-severe plaque psoriasis, meeting all primary and secondary endpoints [4] - Across both trials, 74% of patients achieved PASI 75 and 59% reached sPGA 0/1 at Week 16. By Week 24, about 65% achieved PASI 90, and more than 40% achieved PASI 100, outperforming Amgen's Otezla on all PASI endpoints. The drug was well tolerated, with plans for additional data presentations and an NDA submission in the second half of 2026 [5] Micron Technology Inc. - Micron shares increased by 10.02%, closing at $343.43, with an intraday high of $344.55 and a low of $318.06. The stock traded at a single-digit forward multiple of about 9.8x, indicating a potential earnings reset tied to AI-driven memory demand and a recovery in pricing [6][7] Ventyx Biosciences Inc. - Ventyx shares rose by 28.52%, closing at $10.05, with an intraday high of $25 and a low of $7.08. The stock surged nearly 62.6% to $16.34 in extended trading [8] - Eli Lilly is reportedly in advanced talks to acquire Ventyx for over $1 billion, which would enhance Lilly's portfolio with drugs targeting inflammatory bowel diseases and treatments for Parkinson's disease [9] Western Digital Corporation - Western Digital shares gained 16.77%, closing at $219.38, with an intraday high of $221.23 and a low of $188.36. The stock's surge was driven by expectations of rising memory prices amid a global supply crunch, benefiting peers like SanDisk and Seagate [10]

美国生物制药公司Ventyx Biosciences(VTYX.US)夜盘飙升66%，报16.68美元。 本文源自：金融界AI电报 ...

美国生物制药公司Ventyx Biosciences(VTYX.US)夜盘飙升66%，报16.68美元。消息面上，据华尔街日报 引述消息称，礼来就拟以超过10亿美元收购Ventyx Biosciences的交易进行深入谈判。潜在收购Ventyx将 为礼来的产品管线增加治疗炎症性肠病的药物，以及治疗帕金森等疾病的药物。此外，Ventyx的一种实 验性药物目前正在中期开发阶段，用于治疗与肥胖相关的心血管疾病。(格隆汇) ...

Core Viewpoint - Eli Lilly is in late-stage negotiations to acquire biotech company Ventyx Biosciences for over $1 billion, leading to a 57% surge in Ventyx's stock price after market close [1]. Company Overview - Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for autoimmune diseases, inflammatory diseases, and neurodegenerative diseases [2]. - The company's core pipeline includes NLRP3 inhibitors, with key products VTX2735 and VTX3232, both in Phase 2 development [2][3]. Product Pipeline and Clinical Development - VTX2735 is a peripheral NLRP3 inhibitor targeting recurrent pericarditis, with Phase 2 data expected in the second half of 2025 [3][4]. - VTX3232 is a CNS-penetrant NLRP3 inhibitor aimed at treating Parkinson's disease and cardiometabolic diseases, with positive Phase 2a data anticipated in June 2025 and additional data expected in the second half of 2025 [3][4]. - The inflammatory bowel disease portfolio includes Tamuzimod, a Phase 3-ready S1P1R modulator for ulcerative colitis, and VTX958, a TYK2 inhibitor for Crohn's disease, which has completed Phase 2 trials [3][4]. Financial Position - As of March 31, 2025, Ventyx reported cash, cash equivalents, and marketable securities totaling $228.8 million, expected to fund operations into at least the second half of 2026 [3].

对文泰克斯公司的潜在收购将使礼来获得治疗炎症性肠病（如克罗恩病和溃疡性结肠炎）的药物，同时 还将获得治疗帕金森症等疾病的药物。 文泰克斯公司的一种实验性药物目前正处于治疗与肥胖相关的心血管疾病这一阶段的研发过程中。 据知情人士透露，礼来公司正在就收购文泰克斯生物科学公司（Ventyx Biosciences）进行深入谈判，交 易金额可能超过 10 亿美元。 受此消息推动，文泰克斯公司的股价在盘后交易中上涨了超过 50%。 责任编辑：于健 SF069 据知情人士透露，礼来公司正在就收购文泰克斯生物科学公司（Ventyx Biosciences）进行深入谈判，交 易金额可能超过 10 亿美元。 受此消息推动，文泰克斯公司的股价在盘后交易中上涨了超过 50%。 对文泰克斯公司的潜在收购将使礼来获得治疗炎症性肠病（如克罗恩病和溃疡性结肠炎）的药物，同时 还将获得治疗帕金森症等疾病的药物。 文泰克斯公司的一种实验性药物目前正处于治疗与肥胖相关的心血管疾病这一阶段的研发过程中。 责任编辑：于健 SF069 ...

IBD, IBD Digital, IBD Live, IBD Weekly, Investor's Business Daily, Leaderboard, MarketDiem, MarketSurge and other marks are trademarks owned by Investor's Business Daily, LLC. ©2026 Investor's Business Daily, LLC. All Rights Reserved. Terms of Use Privacy Notice Accessibility About Us Reviews Site Map Your Ad Choices Advertising Contact us IBD Stock Charts IBD Stock Checkup Stock Quotes Stock Market Today The Big Picture My Stock Lists IBD Live Leaderboard SwingTrader MarketSurge IBD Digital MarketDiem The ...

Eli Lilly is in advanced talks to buy Ventyx Biosciences for over $1 billion, the Wall Street Journal reported on Tuesday, citing people familiar with the matter. ...

Core Viewpoint - Telecom Italia (TIM) and Swisscom's Italian unit Fastweb are close to finalizing a mobile network-sharing agreement aimed at reducing costs associated with upgrading and operating their 5G infrastructure in Italy [1] Group 1 - The collaboration between TIM and Fastweb is focused on enhancing the efficiency of their 5G networks [1] - The deal is expected to significantly lower operational costs for both companies as they upgrade their infrastructure [1] - Sources indicate that the agreement is nearing completion, highlighting the urgency and importance of cost management in the telecom sector [1]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Ventyx Biosciences, Inc. and its officers or directors [1]. Group 1: Company Developments - On December 2, 2025, Ventyx announced a revision of its guidance for topline data release from the interim analysis of its Phase 2 study of VTX2735, now expected in Q1 2026 [3]. - The CEO indicated that this shift allows for the introduction of dose-ranging studies with a new once-daily formulation and expansion into Canada, the EU, and the UK, which is believed to accelerate Phase 3 timelines [3]. - Following this announcement, Ventyx's stock price decreased by $1.44 per share, or 15.35%, closing at $7.94 per share on the same day [3]. Group 2: Legal Investigation - Pomerantz LLP is reaching out to investors of Ventyx to discuss claims related to potential securities fraud [1]. - The firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4].